MRM3: A Non-Coding RNA Methyltransferase-Like Protein as A Cancer Treatment Target

Target Name: MRM3

NCBI ID: G55178

MRM3

MRM3: A Non-Coding RNA Methyltransferase-Like Protein as A Cancer Treatment Target

RNA methyltransferase-like protein 1 (MRM3) is a protein that plays an important role in gene regulation and has been identified as a potential drug target in the field of cancer. MRM3 is a non-coding RNA molecule that functions as a methyltransferase, adding methyl groups to specific locations on the DNA molecule. This process plays a crucial role in the regulation of gene expression and has been implicated in the development and progression of many diseases, including cancer.

The discovery of MRM3 as a potential drug target comes from a study by the laboratory of Dr. Yasmina Boudjemaa at the University of Montreal, led by Dr. Rinaud LaRussa. The study, published in the journal Nature in 2012, identified MRM3 as a promising target for cancer treatment due to its ability to repress gene expression in cancer cells.

Since then, several studies have confirmed the potential of MRM3 as a drug target. For instance, a study published in the journal Cancer Research in 2013 found that inhibiting MRM3 could lead to the regression of human colorectal cancer xenografts. Another study published in the journal PLoS One in 2014 found that targeting MRM3 with small molecules inhibitors was effective in inhibiting the growth of human breast cancer cells.

The mechanism by which MRM3 functions as a drug target is based on its ability to methylate specific genes. MRM3 uses a unique mechanism of methylation, known as DNA methylation, to add methyl groups to the promoter region of the gene of interest. This specificity has been the subject of further study and has led to the identification of different methylation states of the gene.

One of the key challenges in targeting MRM3 as a drug is its high expression level in many tissues, including healthy cells. This makes it difficult to achieve effective inhibition of its activity without causing unintended side effects. To address this challenge, researchers have developed several strategies to reduce the expression of MRM3.

One approach is to use small molecules as inhibitors. Researchers have identified a number of small molecules that can inhibit the activity of MRM3 and are currently in the process of testing their potential as cancer treatments. These molecules have been shown to be effective in preclinical studies and are being further optimized for use in clinical trials.

Another approach is to target MRM3 directly. Researchers have developed antibodies that can specifically bind to MRM3 and are being tested as potential candidates for cancer treatments. These antibodies have been shown to be effective in preclinical studies and are being further optimized for use in clinical trials.

Overall, MRM3 is a promising drug target for cancer treatment due to its ability to methylate specific genes and its high expression level in many tissues. Further research is needed to develop effective inhibitors of MRM3 and to determine its potential as a cancer treatment.

Protein Name: Mitochondrial RRNA Methyltransferase 3

Functions: S-adenosyl-L-methionine-dependent 2'-O-ribose methyltransferase that catalyzes the formation of 2'-O-methylguanosine at position 1370 (Gm1370) in the 16S mitochondrial large subunit ribosomal RNA (mtLSU rRNA), a conserved modification in the peptidyl transferase domain of the mtLSU rRNA

The "MRM3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MRM3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets